MedTrace Logo

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

NCT06783816 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-01-20

No results posted yet for this study

Summary

The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.

Conditions

  • Acute Lymphocytic Leukemia
  • Lymphoma,Non-Hodgkin
  • Relapsed Refractory Multiple Myeloma

Interventions

DRUG

chimeric antigen receptor gene modified T cells

The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.

Sponsors & Collaborators

  • Shanxi Bethune Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2028-06-01
Completion
2028-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06783816 on ClinicalTrials.gov